Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

Exclusion Criteria

• •Age \< 18 years old.
• •Pregnancy.
• •Currently using or have used within 3 months of the initial baseline visit any biologic or immunomodulatory therapy with the exception of #3.
• •Currently using or any prior use of rituximab.
• •History of upper/lower respiratory tract infection or asthma exacerbation within the previous four weeks of the first baseline visit.
• •Any prior history of malignancy, autoimmune disease, or immune deficiency.
• •Any other significant medical issue as determined by the principal investigator.